CBP-1019

Bi-Ligand-Drug Conjugate · Coherent Biopharma (Hefei) Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CBP-1019, covering 2024-08-26 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin [Phase 1]

See pricing